mutational landscape determines sensitivity pd blockade non-small cell lung cancer 
immune checkpoint inhibitors unleash patients t cells kill tumors revolutionizing cancer treatment unravel genomic determinants response therapy used whole-exome sequencing non-small cell lung cancers treated pembrolizumab antibody targeting programmed cell death pd- two independent cohorts higher nonsynonymous mutation burden tumors associated improved objective response durable clinical benefit progression-free survival efficacy also correlated molecular smoking signature higher neoantigen burden dna repair pathway mutations factor also associated mutation burden one responder neoantigen-specific cd8+ t cell responses paralleled tumor regression suggesting anti-pd therapy enhances neoantigen-specific t cell reactivity results suggest genomic landscape lung cancers shapes response anti-pd therapy 
